Enhanced Docetaxel Liposomal Composition for Targeted Cancer Therapy

An improved docetaxel liposomal composition with enhanced stability, increased residence time in blood, and reduced toxicity, enabling more efficient and targeted cancer treatment.

The original patent disclosed a docetaxel liposomal composition with high drug loading, but it had limitations in terms of stability, residence time, and toxicity. The new inventive concept addresses these limitations by introducing a combination of solvents, excipients, and pH adjusting agents to achieve improved stability, increased residence time, and reduced toxicity.

The new inventive concept comprises a system for preparing a docetaxel liposomal composition with improved stability, comprising a combination of solvents in a specific ratio to achieve more than 90% drug loading. The composition also includes an excipient that facilitates intravenous administration, and a lyoprotectant to preserve the liposomes during lyophilization. The pH of the composition is adjusted to less than 3.5 to enhance stability. The inventive concept also includes a method for increasing the residence time of docetaxel in blood, reducing toxicity, and targeting tumor sites using the improved liposomal composition.

The new claims introduce a novel combination of solvents, excipients, and pH adjusting agents that improve the stability, residence time, and reduce toxicity of the docetaxel liposomal composition, which is not obvious from the original patent. The inventive concept provides a non-obvious solution to the limitations of the original patent.

Alternative embodiments of the inventive concept may include varying the ratio of solvents, using different excipients or lyoprotectants, or adjusting the pH range. Variations may also include using different types of lipids or cholesterol, or incorporating additional agents to enhance targeting or efficacy.

The enhanced docetaxel liposomal composition has significant commercial potential in the cancer therapy market, particularly in the treatment of solid tumors. The improved stability, increased residence time, and reduced toxicity of the composition make it an attractive option for pharmaceutical companies and researchers seeking to develop more effective and targeted cancer treatments.